Aardvark Therapeutics, Inc. (AARD) Live Share Price, Invest From India

Aardvark Therapeutics, Inc. Stock Performance

as on October 3, 2026 at 2:16 pm IST

Day's Low
Day's High
$4.90
Day's Price Range
$5.66
$4.99
1.80%
Downside
13.43%
Upside
52 Week's Low
52 Week's High
$3.35
52-Week Price Range
$17.94
$4.99
32.87%
Downside
259.52%
Upside

Aardvark Therapeutics, Inc. share price movements today

Previous Close: $5.27
Open: $5.40
Volume: 426.6K
Market Cap: $115.3M
Day's Low - High: $4.90 - $5.66
52 Week Low - High: $3.35 - $17.94

Aardvark Therapeutics, Inc. Historical Returns

1 Month Return: -12.91 %
3 Month Return: -12.46 %
1 Year Return: -68.97 %
3 Year Return: 0 %
5 Year Return: 0 %

Aardvark Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Aardvark Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$115.3M

EPS (TTM)

-3.21

Dividend Yield

0.00%

PE Ratio (TTM)

-1.67

Industry PE ratio

-3.02

PEG Ratio

0.03

Return On Equity TTM

-71.54%

Aardvark Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aardvark Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Aardvark Therapeutics, Inc.	Neutral	$115.3M	NA	-1.67	0.00%	0.00%
Revolution Medicines	StrongBuy	$44.1B	609.62%	-23.34	0.00%	0.00%
Moderna	Neutral	$75.4B	-44.29%	-24.08	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$132.5B	180.98%	30.19	86.04%	0.00%
Regeneron	Buy	$78.1B	28.80%	17.67	84.86%	0.50%

Stock Returns calculator for Aardvark Therapeutics, Inc. Stock including INR - Dollar returns

The Aardvark Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Aardvark Therapeutics, Inc. investment value today

Current value as on today

₹33,678

Returns

-₹66,322

(-66.32%)

Returns from Aardvark Therapeutics, Inc. Stock

-₹68,968 (-68.97%)

Dollar Impact

₹2,646 (+2.65%)

Analyst Recommendation on Aardvark Therapeutics, Inc. Stock

Based on 5 analysts

HOLD

20.00%

Buy

60.00%

Hold

20.00%

Sell

Based on 5 analysts, 60% of analysts recommend a 'HOLD' rating for Aardvark Therapeutics, Inc.. Average target price of $6

Indian Investors' Interest in Aardvark Therapeutics, Inc. Stock

Search interest for Aardvark Therapeutics, Inc. Stock has decreased by -62% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 3, 2026 to October 3, 2026

Change:-62% versus previous 30 day period

Aardvark Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Income	-2	-2	-6	-5	-10	-15	-17	-18	-22	-15
EBITDA	-2	-2	-6	-4	-9	-14	-16	-17	-21	-14
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-2	-2	-5	-4	-9	-14	-16	-17	-21	-14
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-2	-2	-5	-4	-9	-14	-16	-17	-21	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Aardvark Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Mar 2025	Dec 2025
Total Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Income	-11	-7	-22	-62
EBITDA	-10	-6	-22	-57
Interest Expense	-	-	-	-
Depreciation	0	0	0	0
Income Before Tax	-13	-7	-20	-57
Income Tax Expense	-	-	-	-
Net Income	-13	-7	-20	-57
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

Aardvark Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-2	-2	-5	-4	-9	-14	-16	-17	-21	-14
Operating Cash Flow	-1	-2	-4	-3	-11	-9	-18	-14	-18	-17
Investing Cash Flow	-	0	0	0	-112	9	29	24	34	28
Financing Cash Flow	-	-	82	0	88	0	2	-2	0	0
Change in Cash	-1	-2	78	-3	-35	0	13	7	15	11

Aardvark Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Mar 2025	Dec 2025
Net Income	-13	-7	-20	-57
Operating Cash Flow	-10	-5	-18	-54
Investing Cash Flow	-1	-	-11	-49
Financing Cash Flow	0	-	81	89
Change in Cash	-11	-5	51	-14

Global Institutional Holdings in Aardvark Therapeutics, Inc.

Check out the Institutions with significant holdings in Aardvark Therapeutics, Inc..

Funds	Holdings
Vanguard	2.51%
VANGUARD INDEX FUNDS	2.47%
iShares	0.79%
Fidelity Salem Street Trust	0.64%
Fidelity Concord Street Trust	0.56%

See all

Insights on Aardvark Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 635.9%
NEGATIVE IMPACT
Price Dip
In the last 1 year, AARD stock has moved down by -69.0%

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Organisation	Aardvark Therapeutics, Inc.
Headquarters	4370 La Jolla Village Drive, San Diego, CA, 92122, US
Industry	Biotechnology
CEO	Tien-Li Lee

Key Management of Aardvark Therapeutics, Inc.

Name	Title
Mr. Ron Lewis II, Ph.D.	VP & Head of CMC
Mr. Justin T. Stege Ph.D.	VP and Head of Project Management & Strategy
Mr. Derrick C. Li	Chief Business Officer
Dr. Bryan Jones Ph.D.	Chief Executive Officer of Ardia
Dr. Tien-Li Lee M.D.	CEO, Secretary & Chairman
Dr. Manasi Sinha Jaiman M.D., M.P.H.	Chief Medical Officer
Dr. Dvorit Samid Ph.D.	Executive Vice President of Medical Affairs
Dr. Zhenhuan Zheng Ph.D.	Chief Research Officer
Mr. Nelson B. Sun M.B.A.	CFO & COO

FAQs

What is Aardvark Therapeutics, Inc. share price today?

Aardvark Therapeutics, Inc. share price today is $4.99 as on October 3, 2026 at 8:46 am IST at the close of the market. Aardvark Therapeutics, Inc. share today touched a day high of $5.66 and a low of $4.90.

What is the 52 week high and 52 week low for Aardvark Therapeutics, Inc. share?

Aardvark Therapeutics, Inc. share touched a 52 week high of $17.94 on October 8, 2025 and a 52 week low of $3.35 on March 27, 2026. Aardvark Therapeutics, Inc. stock price today i.e. October 3, 2026 at 8:46 am IST is closed at $4.99,which is 72.19% down from its 52 week high and 48.96% up from its 52 week low.

What is Aardvark Therapeutics, Inc.'s market capitalisation today?

Aardvark Therapeutics, Inc. market capitalisation is $0.00T as on October 3, 2026 at 8:46 am IST.

How to invest in Aardvark Therapeutics, Inc. Stock (AARD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aardvark Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aardvark Therapeutics, Inc. Stock (AARD) from India?

Indian investors can start investing in Aardvark Therapeutics, Inc. (AARD) shares with as little as ₹96.300003051758 or $1 (as of October 3, 2026 at 4:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Aardvark Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on October 3, 2026 at 4:39 pm IST). Based on Aardvark Therapeutics, Inc. share’s latest price of $4.99 as on October 3, 2026 at 8:46 am IST, you will get 2.0040 shares of Aardvark Therapeutics, Inc.. Learn more about fractional shares .